Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A subtype of type I autosomal dominant cerebellar ataxia (ADCA type I) characterized by truncal ataxia, dysarthria, slowed saccades and less commonly ophthalmoparesis and chorea.
Features include always present findings: Ataxia and Dysarthria; and common findings: Shrinkage of the cerebellum (cerebellar atrophy), Urinary incontinence, Unsteady gait, and Difficulty swallowing (dysphagia) and others. 37 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 17 | Action tremor, Slowness of movement (bradykinesia), Muscle stiffness (rigidity) |
Muscles | 5 | Olivopontocerebellar atrophy, Shrinkage of the cerebellum (cerebellar atrophy), Low muscle tone (hypotonia) |
Eyes | 4 | Gaze-evoked nystagmus, Slow saccadic eye movements, Oculomotor apraxia |
Kidneys and urinary system | 2 | Urinary incontinence, Urinary bladder sphincter dysfunction |
Bones and joints | 2 | Postural tremor, Postural instability |
Digestive system | 1 | Difficulty swallowing (dysphagia) |
Arms and legs | 1 | Limb ataxia |
Spinocerebellar ataxia type 2 (SCA2) is characterized by slowly progressive ataxia and dysarthria associated with the ocular findings of nystagmus, slow saccadic eye movements, and in some individuals, ophthalmoparesis. Tendon reflexes are brisk during the first years of life, but absent later. Mean age of onset is typically in the fourth decade with a ten- to 15-year disease duration. The disease is more rapidly progressive when onset occurs before age 20 years. In the original study from Cuba, the earliest symptoms included gait ataxia often accompanied by leg cramps . More than 50% of affected individuals developed a kinetic or postural tremor, decreased muscle tone, decreased tendon reflexes, and abnormal eye movements with slowed saccades progressing to supranuclear ophthalmoplegia.
Source: GeneReviews — "Spinocerebellar Ataxia Type 2"
ATXN2 encodes ataxin 2 (1,313 aa). Involved in EGFR trafficking, acting as negative regulator of endocytic EGFR internalization at the plasma membrane Highest expression in Ovary (36.2 TPM) and Nerve Tibial (33.7 TPM).
Spinocerebellar ataxia type 2 is caused by mutations in the ATXN2 gene on chromosome 12.
ATXN2 is classified as a druggable target with score 0.2.
Probands. In general, a clear inverse correlation exists between age of onset and CAG repeat length. However, repeat length cannot predict age of onset or disease severity in an individual. About 50% of age-of-onset variance is not explained by CAG repeat length .
The widest range of age of onset is observed among individuals with fewer than 40 CAG repeats. Some individuals with alleles of 33 and 34 repeats have had onset after age 60 years. In one study, the presence of 37 repeats was associated with ages of onset ranging from 20 to 60 years .
For larger repeat sizes, the variability in age of onset is less; repeat sizes greater than 45 are almost always associated with disease onset before age 20 years [, , , , , , ].
Source: GeneReviews — "Spinocerebellar Ataxia Type 2"
Spinocerebellar ataxia type 2 (SCA2) should be suspected in individuals with the following:
Slowly progressive ataxia and dysarthria
Nystagmus and slow saccadic eye movements
Family history consistent with autosomal dominant inheritance
The diagnosis of SCA2 is established in a proband with a heterozygous pathogenic variant in ATXN2 . The clinical features of SCA2 do not allow diagnosis with certainty; thus, diagnosis depends on molecular genetic testing.
Allele sizes
Source: GeneReviews — "Spinocerebellar Ataxia Type 2"
It is difficult and often impossible to distinguish spinocerebellar ataxia type 2 (SCA2) from the other hereditary ataxias (see Hereditary Ataxia Overview). The differential diagnosis should also include Parkinson disease and acquired causes of cerebellar ataxia. SCA2-related ATXN2 pathogenic variants should be in the differential diagnosis of adult-onset sporadic progressive ataxia, multiple system atrophy (MSA, Shy-Drager syndrome; OMIM 146500), L-dopa-responsive parkinsonism, atypical Friedreich ataxia , and amyotrophic lateral sclerosis . Table 2. Proportion of Individuals with SCA2 Manifesting Phenotypic Features Compared with Individuals with SCA1, SCA3, and SCA6
Phenotypic Feature | SCA2 | SCA1 | SCA3 | SCA6 |
|---|---|---|---|---|
Cerebellar dysfunction |
Genetic testing for ATXN2 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for spinocerebellar ataxia type 2 has been reported in the published literature.
No approved treatments are currently available for spinocerebellar ataxia type 2. The disease remains an area of unmet medical need.
To establish the extent of disease and needs in an individual diagnosed with spinocerebellar ataxia type 2 (SCA2), the evaluations summarized in this section (if not performed as part of the evaluation that led to the diagnosis) are recommended:
Neurologic examination
Ophthalmologic examination
Baseline assessment of cognition
Neuroimaging
Consultation with a clinical geneticist and/or genetic counselor
Management of individuals remains supportive as no known therapy to delay or halt the progression of the disease exists. Although neither exercise nor physical therapy has been shown to stem the progression of incoordination or muscle weakness, individuals should maintain activity. Canes and walkers help prevent falls. Modification of the home with such conveniences as grab bars, raised toilet seats, and ramps to accommodate motorized chairs may be necessary. Speech therapy and communication devices such as writing pads and computer-based devices may benefit those with dysarthria. Weighted eating utensils and dressing hooks help maintain a sense of independence. When dysphagia becomes troublesome, video esophagrams can identify the consistency of food least likely to trigger aspiration. Improvement of severe tremor with thalamic stimulation has been reported in one individual . Another individual showed improvement with stimulation of the subthalamic nucleus .
Source: GeneReviews — "Spinocerebellar Ataxia Type 2"
Alcohol and medications known to affect cerebellar function should be avoided.
Source: GeneReviews — "Spinocerebellar Ataxia Type 2"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Spinocerebellar Ataxia Type 2"
6 trials found
Affected individuals should be examined at least annually by a physician experienced in movement disorders and ataxia.
Source: GeneReviews — "Spinocerebellar Ataxia Type 2"
Phenotype severity distribution: 2 always present features, 5 common features.
Estimated prevalence: 1-9 in 100,000 (Uncommon).
6 clinical trials registered, 1 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 2 PHASE3, 1 PHASE2, 1 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT03408080](https://clinicaltrials.gov/study/NCT03408080) | Open Pilot Trial of BHV-4157 | PHASE3 | University of California, Los Angeles | ACTIVE_NOT_RECRUITING |
[NCT01793168](https://clinicaltrials.gov/study/NCT01793168) | Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford | — | Sanford Health | RECRUITING |
[NCT03378414](https://clinicaltrials.gov/study/NCT03378414) | Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia | PHASE2 | Sclnow Biotechnology Co., Ltd. | NOT_YET_RECRUITING |
[NCT06672445](https://clinicaltrials.gov/study/NCT06672445) | Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2 | PHASE1 | Arrowhead Pharmaceuticals | ACTIVE_NOT_RECRUITING |
[NCT05826171](https://clinicaltrials.gov/study/NCT05826171) | Priming Motor Learning Through Exercise in People With Spinocerebellar Ataxia | NA | Teachers College, Columbia University | UNKNOWN |
60 publications have been identified in PubMed for spinocerebellar ataxia type 2. Research spans Basic Science / Preclinical (40%), Case Report / Case Series (15%), and Epidemiology / Natural History (15%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 24 | 40% |
Patient case studies | 9 | 15% |
Disease patterns and progression | 9 | 15% |
Testing and diagnosis research | 6 | 10% |
Research summaries | 6 | 10% |
New treatment approaches | 4 |
Asherah N (2026). [PMID: 41683965](https://pubmed.ncbi.nlm.nih.gov/41683965/). *International journal of molecular sciences*. [Gene Therapy / Novel Therapeutics]
Auburger G (2026). [PMID: 42041567](https://pubmed.ncbi.nlm.nih.gov/42041567/). *Cells*. [Basic Science / Preclinical]
Sonakar AK (2026). [PMID: 41693683](https://pubmed.ncbi.nlm.nih.gov/41693683/). *Annals of Indian Academy of Neurology*. [Epidemiology / Natural History]
Vieira AA (2026). [PMID: 41770293](https://pubmed.ncbi.nlm.nih.gov/41770293/). *Cerebellum*. [Basic Science / Preclinical]
Zamora-Fung R (2026). [PMID: 41831049](https://pubmed.ncbi.nlm.nih.gov/41831049/). *Cerebellum*. [Basic Science / Preclinical]
Wang H (2026). [PMID: 41831135](https://pubmed.ncbi.nlm.nih.gov/41831135/). *Cerebellum*. [Case Report / Case Series]
Auburger GWJ (2026). [PMID: 41683920](https://pubmed.ncbi.nlm.nih.gov/41683920/). *International journal of molecular sciences*. [Basic Science / Preclinical]
Velázquez-Pérez L (2026). [PMID: 41876820](https://pubmed.ncbi.nlm.nih.gov/41876820/). *Cerebellum*. [Epidemiology / Natural History]
Vázquez-Mojena Y (2026). [PMID: 42019185](https://pubmed.ncbi.nlm.nih.gov/42019185/). *J Neuroimmunol*. [Basic Science / Preclinical]
Vilella D (2026). [PMID: 42060068](https://pubmed.ncbi.nlm.nih.gov/42060068/). *Cerebellum*. [Case Report / Case Series]
Data assembled from 9 of 12 sources · Last updated Sep 19, 2026, 6:47 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
100% |
100% |
100% |
Reduced saccadic velocity | 71%-92% | 50% | 10% | 0%-6% |
Myoclonus | 0%-40% | 0% | 4% | 0% |
Dystonia or chorea | 0%-38% | 20% | 8% | 0%-25% |
Pyramidal involvement | 29%-31% | 70% | 70% | 33%-44% |
Peripheral neuropathy | 44%-94% | 100% | 80% | 16%-44% |
Intellectual impairment | 31%-37% | 20% | 5% | 0% Percentages modified from , , , and |
Source: GeneReviews — "Spinocerebellar Ataxia Type 2"
Clinical study results | 2 | 3% |
AI-curated news mentioning spinocerebellar ataxia type 2
Updated Mar 14, 2026
A new study provides clinical and genetic insights into pediatric-onset spinocerebellar ataxia type 2, highlighting its rare nature and potential implications for diagnosis and treatment. This research contributes to the understanding of the disease's genetic underpinnings.